Evidence map›Paper›PMID 35665067›Full record

ArticleFrontiers in chemistry2022

Design, Synthesis, and Apoptosis-Promoting Effect Evaluation of Rhopaladins' Analog 4-Arylidene-5-Oxopyrrolidine Derivatives.

Jun Zhu, Ling-Qi Kong, Qin-Hua Chen, Bin Li, Lun Wu, Feng-Ying Ran, Li-Na Ke, Xiao-Hua Zeng, Hong-Mei Wang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Jun ZhuSinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, China.
Ling-Qi KongHubei Key Laboratory of Wudang Local Chinese Medicine Research, School of Pharmaceutical Sciences, Hubei University of Medicine, Hubei, China.
Qin-Hua ChenShenzhen Baoan Authentic TCM Therapy Hospital, Shenzhen, China.
Bin LiSinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, China.
Lun WuSinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, China.
Feng-Ying RanSinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, China.
Li-Na KeSinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, China.
Xiao-Hua ZengSinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, China.
Hong-Mei WangSinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, China.
China National Pharmaceutical Group Corporation (China) · CNHubei University of Chinese Medicine · CNHubei University of Medicine · CNDongfeng General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Marine alkaloids have novel structures and antitumor activities. Therefore, we synthesized rhopaladins' analogs from marine alkaloids rhopaladins A-D and modified their structures to synthesize 4-benzylidene-5-pyrrolidone derivatives. Among the compounds, (2

Indexed as

4-arylidene-5-oxopyrrolidineanticancerapoptosiscytotoxicity evaluationrhopaladins’ analogsynthesis

Identifiers

PMID35665067
PMCPMC9157788
OpenAlexW4280522559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.